Nigeria

Population 2018: 196 million

### Tuberculosis Profile

#### Population 2018: 196 million

### Estimates of TB burden*, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>429 (280–609)</td>
<td>219 (143–311)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>53 (34–75)</td>
<td>27 (17–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>21 (13–32)</td>
<td>11 (6.4–16)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>130 (73–190)</td>
<td>64 (37–98)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>32 (20–47)</td>
<td>16 (10–24)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- **New cases**: 4.3% (3.2–5.5)
- **Previously treated cases**: 15% (11–19)

### TB Case Notifications, 2018

- Total new and relapse: 103,921
  - % tested with rapid diagnostics at time of diagnosis: 54%
  - % with known HIV status: 100%
  - % pulmonary: 96%
  - % bacteriologically confirmed**: 77%
  - % children aged 0–14 years: 8%
  - % women: 34%
  - % men: 58%

- Total cases notified: 106,533

### Universal Health Coverage and Social Protection

- TB treatment coverage (notified/estimated incidence), 2018: 24% (17–37)
- TB patients facing catastrophic total costs, 2017: 71% (68–73)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 38% (19–59)

### TB/HIV care in new and relapse TB patients, 2018

- Patients with known HIV status who are HIV-positive
  - % on antiretroviral therapy: 12,700/12%
  - Number: 11,032/87%

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 65%
  - New cases: 65%
  - Previously treated cases: 88%

### Laboratory-confirmed cases*

- MDR/RR-TB: 2,275, XDR-TB: 31
- Patients started on treatment**
  - MDR/RR-TB: 1,895, XDR-TB: 14
  - Number: 1,895

### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 86% (101,734)
- Previously treated cases, excluding relapse, registered in 2017: 82% (2,781)
- HIV-positive TB cases registered in 2017: 76% (13,851)
- MDR/RR-TB cases started on second-line treatment in 2016: 77% (1,251)
- XDR-TB cases started on second-line treatment in 2016: 100%

### TB Preventive Treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 62%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 19% (17–21)

### TB Financing, 2019

- National TB budget (US$ millions): 278
- Funding source: 8% domestic, 32% international, 60% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
**: Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-12-31 Data: www.who.int/tb/data